Gilead Sciences (NASDAQ:GILD) Coverage Initiated by Analysts at SVB Leerink

Equities researchers at SVB Leerink began coverage on shares of Gilead Sciences (NASDAQ:GILDGet Rating) in a research report issued on Monday, The Fly reports. The firm set a “market perform” rating on the biopharmaceutical company’s stock.

A number of other equities analysts also recently issued reports on GILD. Mizuho decreased their price objective on Gilead Sciences from $81.00 to $75.00 and set a “buy” rating for the company in a report on Tuesday, February 8th. Maxim Group reduced their price target on Gilead Sciences from $88.00 to $84.00 in a report on Thursday, February 3rd. Wells Fargo & Company reduced their price target on Gilead Sciences from $70.00 to $63.00 and set an “equal weight” rating for the company in a report on Tuesday, March 22nd. Barclays reduced their price target on Gilead Sciences from $63.00 to $56.00 and set an “underweight” rating for the company in a report on Thursday, March 10th. Finally, Bank of America reduced their price objective on Gilead Sciences from $73.00 to $71.00 and set a “neutral” rating for the company in a report on Wednesday, February 2nd. One analyst has rated the stock with a sell rating, nine have issued a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat, Gilead Sciences presently has an average rating of “Hold” and a consensus target price of $72.67.

NASDAQ GILD opened at $63.84 on Monday. The firm’s 50-day simple moving average is $61.08 and its two-hundred day simple moving average is $65.14. Gilead Sciences has a 52 week low of $57.19 and a 52 week high of $74.12. The company has a market cap of $80.08 billion, a PE ratio of 17.83, a price-to-earnings-growth ratio of 0.45 and a beta of 0.38. The company has a quick ratio of 1.30, a current ratio of 1.48 and a debt-to-equity ratio of 1.31.

Gilead Sciences (NASDAQ:GILDGet Rating) last posted its quarterly earnings data on Thursday, April 28th. The biopharmaceutical company reported $2.12 earnings per share for the quarter, topping the consensus estimate of $1.77 by $0.35. The company had revenue of $6.59 billion for the quarter, compared to analysts’ expectations of $6.28 billion. Gilead Sciences had a net margin of 16.43% and a return on equity of 44.98%. Gilead Sciences’s revenue for the quarter was up 2.6% compared to the same quarter last year. During the same period in the prior year, the business earned $2.08 earnings per share. As a group, equities research analysts anticipate that Gilead Sciences will post 6.6 EPS for the current year.

In related news, EVP Brett A. Pletcher sold 3,634 shares of the company’s stock in a transaction that occurred on Friday, March 11th. The stock was sold at an average price of $58.24, for a total value of $211,644.16. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 0.16% of the stock is currently owned by corporate insiders.

Several hedge funds have recently added to or reduced their stakes in the company. Greylin Investment Mangement Inc. increased its holdings in shares of Gilead Sciences by 21.9% during the 1st quarter. Greylin Investment Mangement Inc. now owns 228,570 shares of the biopharmaceutical company’s stock worth $13,588,000 after buying an additional 41,130 shares during the last quarter. The Manufacturers Life Insurance Company increased its holdings in Gilead Sciences by 0.7% in the 1st quarter. The Manufacturers Life Insurance Company now owns 3,139,511 shares of the biopharmaceutical company’s stock valued at $186,644,000 after purchasing an additional 22,543 shares in the last quarter. Toroso Investments LLC increased its holdings in Gilead Sciences by 12.3% in the 1st quarter. Toroso Investments LLC now owns 70,221 shares of the biopharmaceutical company’s stock valued at $4,175,000 after purchasing an additional 7,679 shares in the last quarter. Capital World Investors increased its holdings in Gilead Sciences by 16.0% in the 1st quarter. Capital World Investors now owns 49,501,852 shares of the biopharmaceutical company’s stock valued at $2,942,905,000 after purchasing an additional 6,820,228 shares in the last quarter. Finally, Golden State Wealth Management LLC acquired a new stake in Gilead Sciences in the 1st quarter valued at $223,000. Institutional investors and hedge funds own 80.16% of the company’s stock.

About Gilead Sciences (Get Rating)

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases.

Read More

The Fly logo

Analyst Recommendations for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.